Homepage Top Section1

This move aims to bolster AstraZeneca’s cardiovascular portfolio in addressing key risk factors associated with chronic cardiovascular diseases. As per the agreement terms, AstraZeneca will gain access to

With the latest development, Otulfi is now intended to treat Crohn’s disease, moderate to severe plaque psoriasis, ulcerative colitis and active psoriatic arthritis. Fresenius Kabi and Formycon signed

The product is the result of a collaboration with the Agency for Science, Technology, and Research (A*STAR), featuring patented active pH control technology to address the skin condition.

The first facility is breaking ground at the Novartis site in Indianapolis, dedicated to the production of radioisotopes essential for RLT manufacturing. This expansion is set to bolster

SKG1108 is a one-time intravitreally delivered therapy, which uses a recombinant adeno-associated virus (rAAV) vector to target the condition. It employs the AAV.0106 capsid to deliver a single-stranded

An armoured allogeneic “off-the-shelf”gamma delta CAR T cell therapy, ADI-270 targets CD70-positive cancers. ADI-270 is engineered to target CD70 by using CD27 as the natural receptor binding moiety.

These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation

Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply